Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Moderator

Ann Childress, MD

Adjunct Faculty, UNLV and Touro University of Nevada
President, Center for Psychiatry and Behavioral Medicine, Inc.
President, American Professional Society for ADHD and Related Disorders
Las Vegas, Nevada

Disclosures

Ann Childress, MD, has the following relevant financial relationships:
Consultant or advisor for: Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Aytu (NEOS Therapeutics, Inc.); Cingulate; Corium International, Inc.; Lumos Pharma; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Sky; Tris Pharma, Inc.; Tulex Pharmaceuticals.
Speaker or member of speakers bureau for: Corium International, Inc.; Ironshore Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Tris Pharma, Inc.
Research funding from: Allergan, Inc.; Akili Interactive Labs, Inc.; Cingulate; Otsuka Pharmaceutical Co., Ltd.; Lumos Pharma; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited (Shire)
Contracted researcher for: Allergan, Inc.; Akili Interactive Labs, Inc.; Cingulate; Otsuka Pharmaceutical Co., Ltd.; Lumos Pharma; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited (Shire)

Faculty

Vladimir Maletic, MD, MS

Clinical Professor of Psychiatry
USC School of Medicine
Greenville, South Carolina

Disclosures

Vladimir Maletic, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alfasigma, USA, Inc.; Alkermes, Inc.; Allergan, Inc.; Eisai Inc.; Intra-Cellular Therapies, Inc.; Ironshore, Pharmaceuticals, Inc.; Janssen Pharmaceuticals; H. Lundbeck A/S; Jazz Pharmaceuticals, Inc.; Noven Pharmaceuticals, Inc; Otsuka America Pharmaceutical, Inc.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited
Speaker or member of speakers bureau for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan, Inc.; Eisai Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals, Inc.; Janssen Pharmaceuticals; H. Lundbeck A/S; Otsuka America Pharmaceutical, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited

Gregory W. Mattingly, MD

Associate Clinical Professor
Washington University School of Medicine
President, Midwest Research Group
President Elect, American Professional Society for ADHD and Related Disorders
St. Louis, Missouri

Disclosures

Gregory W. Mattingly, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Corium International, Inc.; Eisai Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; NEOS Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Redax; Roche; Rhodes Pharmaceuticals L.P.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceuticals USA; Tris Pharma, Inc.
Research funding from: AbbVie Inc.; Alkermes, Inc.; Corium International, Inc.; Eisai Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited.; Tris Pharma, Inc.
Contracted researcher for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Akili Interactive Labs, Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Emalex Biosciences; Idorsia Pharmaceuticals, Ltd.; Janssen Pharmaceuticals; Karuna Therapeutics; Lumos Labs; Medgenics; NLS-1 Pharma AG; Redax; Relmada Therapeutics, Inc.; Roche; Sage Therapeutics, Inc.; Sirtsei Pharmaceuticals Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited.; Teva Pharmaceuticals USA.

Editor

Clinton W. Wright, PharmD, BCPP

Medical Education Director, Medscape, LLC

Disclosures

Clinton W. Wright, PharmD, BCPP, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / CE

Don't Let ADHD Fly Under the Radar: Recognition and Treatment of ADHD in the Context of Comorbidity

Authors: Ann Childress, MD; Vladimir Maletic, MD, MS; Gregory W. Mattingly, MD
CME / CE Released: 2/17/2023
Valid for credit through: 2/17/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

Nurses - 1.00 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians (PCPs), pediatricians, nurse practitioners (NPs), physician assistants (PAs), nurses, and pharmacists, and other clinicians who care for patients with ADHD.

The goal of this activity is for learners to be better able to differentiate ADHD from other psychiatric disorders, describe the latest clinical data on new medications, and individualize treatment approaches for ADHD with a focus on nonstimulants in the adult population.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Considerations of comorbidities when selecting treatment for adult patients with ADHD
Have greater competence related to
- Diagnosis of ADHD
- Using a nonstimulant medication in appropriate patients with ADHD
Demonstrate greater confidence in their ability to
- Individualize management approaches for patients with ADHD based on specific patient characteristics

Disclosures

Moderator

Ann Childress, MD

Adjunct Faculty, UNLV and Touro University of Nevada
President, Center for Psychiatry and Behavioral Medicine, Inc.
President, American Professional Society for ADHD and Related Disorders
Las Vegas, Nevada

Disclosures

Ann Childress, MD, has the following relevant financial relationships:
Consultant or advisor for: Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Aytu (NEOS Therapeutics, Inc.); Cingulate; Corium International, Inc.; Lumos Pharma; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Sky; Tris Pharma, Inc.; Tulex Pharmaceuticals.
Speaker or member of speakers bureau for: Corium International, Inc.; Ironshore Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Tris Pharma, Inc.
Research funding from: Allergan, Inc.; Akili Interactive Labs, Inc.; Cingulate; Otsuka Pharmaceutical Co., Ltd.; Lumos Pharma; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited (Shire)
Contracted researcher for: Allergan, Inc.; Akili Interactive Labs, Inc.; Cingulate; Otsuka Pharmaceutical Co., Ltd.; Lumos Pharma; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited (Shire)

Faculty

Vladimir Maletic, MD, MS

Clinical Professor of Psychiatry
USC School of Medicine
Greenville, South Carolina

Disclosures

Vladimir Maletic, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alfasigma, USA, Inc.; Alkermes, Inc.; Allergan, Inc.; Eisai Inc.; Intra-Cellular Therapies, Inc.; Ironshore, Pharmaceuticals, Inc.; Janssen Pharmaceuticals; H. Lundbeck A/S; Jazz Pharmaceuticals, Inc.; Noven Pharmaceuticals, Inc; Otsuka America Pharmaceutical, Inc.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited
Speaker or member of speakers bureau for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan, Inc.; Eisai Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals, Inc.; Janssen Pharmaceuticals; H. Lundbeck A/S; Otsuka America Pharmaceutical, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited

Gregory W. Mattingly, MD

Associate Clinical Professor
Washington University School of Medicine
President, Midwest Research Group
President Elect, American Professional Society for ADHD and Related Disorders
St. Louis, Missouri

Disclosures

Gregory W. Mattingly, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Corium International, Inc.; Eisai Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; NEOS Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Redax; Roche; Rhodes Pharmaceuticals L.P.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceuticals USA; Tris Pharma, Inc.
Research funding from: AbbVie Inc.; Alkermes, Inc.; Corium International, Inc.; Eisai Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited.; Tris Pharma, Inc.
Contracted researcher for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Akili Interactive Labs, Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Emalex Biosciences; Idorsia Pharmaceuticals, Ltd.; Janssen Pharmaceuticals; Karuna Therapeutics; Lumos Labs; Medgenics; NLS-1 Pharma AG; Redax; Relmada Therapeutics, Inc.; Roche; Sage Therapeutics, Inc.; Sirtsei Pharmaceuticals Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited.; Teva Pharmaceuticals USA.

Editor

Clinton W. Wright, PharmD, BCPP

Medical Education Director, Medscape, LLC

Disclosures

Clinton W. Wright, PharmD, BCPP, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

Developed through a partnership between Medscape Education, APSARD, and Amedco.

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Professional Society of ADHD and Related Disorders (APSARD). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Amedco LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For Nurses

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.

Contact This Provider

For Pharmacists

Amedco LLC designates this continuing education activity for a maximum of 1.0 knowledge-based CPE contact hours (Universal Activity Number: JA4008163-9999-23-043-H01-P).

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Psychiatry & Mental Health

CME / CE

Don't Let ADHD Fly Under the Radar: Recognition and Treatment of ADHD in the Context of Comorbidity

Authors: Ann Childress, MD; Vladimir Maletic, MD, MS; Gregory W. Mattingly, MDFaculty and Disclosures

CME / CE Released: 2/17/2023

Valid for credit through: 2/17/2024, 11:59 PM EST

processing....

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 4

CME / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Moderator

Ann Childress, MD

Faculty

Vladimir Maletic, MD, MS

Gregory W. Mattingly, MD

Editor

Clinton W. Wright, PharmD, BCPP

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CME / CE

Don't Let ADHD Fly Under the Radar: Recognition and Treatment of ADHD in the Context of Comorbidity

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Moderator

Ann Childress, MD

Faculty

Vladimir Maletic, MD, MS

Gregory W. Mattingly, MD

Editor

Clinton W. Wright, PharmD, BCPP

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Don't Let ADHD Fly Under the Radar: Recognition and Treatment of ADHD in the Context of Comorbidity

Learning Feedback Questions